Lactosylceramide alpha-2,3-sialyltransferase

BE0004604ProteinHumansST3GAL5

Transfers the sialyl group (N-acetyl-alpha-neuraminyl or NeuAc) from CMP-NeuAc to the non-reducing terminal galactose (Gal) of glycosphingolipids forming gangliosides (important molecules involved in the regulation of multiple cellular processes, including cell proliferation and differentiation, apoptosis,... It is acted on by 2 drugs in DrugBank.

Gene name
ST3GAL5
UniProtKB entry
Q9UNP4Swiss-Prot
Cellular location
Golgi apparatus membrane
Residues / weight
418 residues · 47,989 Da
Also known as
2.4.3.9 · CMP-NeuAc:lactosylceramide alpha-2,3-sialyltransferase · Ganglioside GM3 synthase · GM3 synthase · Sialyltransferase 9

Resolves to

Protein
UniProtQ9UNP4UniProt nameSIAT9_HUMAN
Gene
HGNCHGNC:10872NCBI Gene8869GeneCardsST3GAL5
Pharmacology
KEGGhsa:8869
Drugs

What you can answer from here — as of September 07, 2019

2DrugsApproved to experimental, with action, bond type and pharmacological action
Sign in
6GO termsFunction, process and component, as structured annotations
Sign in
1Pfam domainDomain architecture mapped to Pfam families and clans
Sign in
12+ReferencesStructured and connected to the statements they support
Sign in

Which approved drugs act on Lactosylceramide alpha-2,3-sialyltransferase, how selective are they, and which programs against it are still in active trials?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In